Page 1 | Search Results | Blood | American Society of Hematology

1-13 of 13

Sort by

Sort Order Select

Journal Articles

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

Blood (2013) 122 (8): 1455–1463.

https://doi.org/10.1182/blood-2013-03-491506

Published: 2013

Includes: Supplemental data

Journal Articles

SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML

May S.K. Sutherland, PhD, Roland B. Walter, MD, PhD, Scott C. Jeffrey, PhD, Patrick J. Burke, PhD, Changpu Yu, MD, Kimberly H. Harrington, BS, Ivan Stone, BS, Maureen C. Ryan, PhD, Django Sussman, PhD, Weiping Zeng, MD, Dennis R. Benjamin, PhD, Irwin D. Bernstein, MD, Peter D. Senter, PhD, Jonathan G. Drachman, MD, Julie A. McEarchern, PhD

Blood (2012) 120 (21): 3589.

https://doi.org/10.1182/blood.V120.21.3589.3589

Published: 2012

Journal Articles

Preclinical and Clinical Binding Properties, Internalization Kinetics, and Clinicopathological Activity of Brentuximab Vedotin (SGN-35): A Novel Antibody Drug Conjugate for Anaplastic Large Cell Lymphoma and Classical Hodgkin Lymphoma

Jonathan R Fromm, MD, PhD, Julie A. McEarchern, PhD, Dana Kennedy, PharmD, Thomas Anju, Andrei R Shustov, MD, Ajay K Gopal, MD

Blood (2010) 116 (21): 1789.

https://doi.org/10.1182/blood.V116.21.1789.1789

Published: 2010

Journal Articles

CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemia

Allen W. Ho, Evdoxia Hatjiharissi, Bryan T. Ciccarelli, Andrew R. Branagan, Zachary R. Hunter, Xavier Leleu, Olivier Tournilhac, Lian Xu, Kelly O'Connor, Robert J. Manning, Daniel Ditzel Santos, Mariana Chemaly, Christopher J. Patterson, Jacob D. Soumerai, Nikhil C. Munshi, Julie A. McEarchern, Che-Leung Law, Iqbal S. Grewal, Steven P. Treon

Blood (2008) 112 (12): 4683–4689.

https://doi.org/10.1182/blood-2007-04-084525

Published: 2008

Journal Articles

Preclinical Analysis of the Combined Activity of SGN-40, Anti-CD40 Monoclonal Antibody, with Rituximab in Non-Hodgkin Lymphoma.

Timothy S. Lewis, Renee S. McCormick, Julie A. McEarchern, Kim Kissler, Ivan J. Stone, Hans-Peter Gerber, Jonathan G. Drachman, Iqbal Grewal, Che-Leung Law

Blood (2008) 112 (11): 1583.

https://doi.org/10.1182/blood.V112.11.1583.1583

Published: 2008

Journal Articles

SGN-33, Lintuzumab, Demonstrates Anti-Leukemic Activity in Preclinical Models of AML.

May S.K. Sutherland, PhD, Changpu Yu, MD, Carol Morris-Tilden, Timothy S. Lewis, PhD, Jamie B. Miyamoto, Julie A. McEarchern, PhD, Ezogelin Oflazoglu, PhD, Hanspeter Gerber, PhD, Eric L. Sievers, MD, Iqbal S. Grewal, PhD, Che-Leung Law, PhD

Blood (2007) 110 (11): 919.

https://doi.org/10.1182/blood.V110.11.919.919

Published: 2007

Journal Articles

SGN-33 Modulates Cytokine and Chemokine Production by Activated Monocytes and Macrophages.

May S.K. Sutherland, PhD, Timothy S. Lewis, PhD, Changpu Yu, MD, Julie A. McEarchern, PhD, Jonathan G. Drachman, MD, Eric L. Sievers, MD, Iqbal S. Grewal, PhD, Che-Leung Law, PhD

Blood (2006) 108 (11): 1995.

https://doi.org/10.1182/blood.V108.11.1995.1995

Published: 2006

Journal Articles

Targeted Depletion and Inhibition of Activated T Lymphocytes with SGN-70, a Humanized Antibody Specific for the Activation Antigen CD70.

Julie A. McEarchern, PhD, Kerry Klussman, B.S., Tamar E. Boursalian, Ph.D., Iqbal S. Grewal, Ph.D., Che-Leung Law, Ph.D.

Blood (2006) 108 (11): 1728.

https://doi.org/10.1182/blood.V108.11.1728.1728

Published: 2006

Journal Articles

Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenström’s Macroglobulinemia (WM).

Evdoxia Hatjiharissi, MD, Allen W. Ho, Lian Xu, Kelly E. O’Connor, Zachary R. Hunter, Daniel D. Santos, MD, Robert Manning, Xavier Leleu, MD, Anne-Sophie Moreau, MD, Christopher J. Patterson, Julie A. McEarchern, PhD, Che-Leung Law, PhD, Iqbal S. Grewal, PhD, Nikhil C. Munshi, MD, PhD, Steven P. Treon, MD, PhD

Blood (2006) 108 (11): 2490.

https://doi.org/10.1182/blood.V108.11.2490.2490

Published: 2006

Journal Articles

SGN-70, a Humanized Anti-CD70 Antibody, Targets CD70-Expressing Hematologic Tumors.

Julie A. McEarchern, PhD, Charlotte F. McDonagh, Ph.D., Leia M. Smith, Ph.D., Kerry Klussman, B.S., Ezogelin Oflazoglu, Ph.D., Carol Morris-Tilden, B.S., Ivan Stone, B.S., Renee McCormick, B.S., Paul Carter, Ph.D., Hanspeter Gerber, Ph.D., Iqbal S. Grewal, Ph.D., Che-Leung Law, Ph.D.

Blood (2006) 108 (11): 2492.

https://doi.org/10.1182/blood.V108.11.2492.2492

Published: 2006

Journal Articles

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities

Julie A. McEarchern, Ezogelin Oflazoglu, Leigh Francisco, Charlotte F. McDonagh, Kristine A. Gordon, Ivan Stone, Kerry Klussman, Eileen Turcott, Nico van Rooijen, Paul Carter, Iqbal S. Grewal, Alan F. Wahl, Che-Leung Law

Blood (2006) 109 (3): 1185–1192.

https://doi.org/10.1182/blood-2006-07-034017

Published: 2006

Journal Articles

The Humanized Anti-CD40 Monoclonal Antibody SGN-40 Targets Hodgkin’s Disease Cells through Multiple Mechanisms.

Che-Leung Law, PhD, Julie A. McEarchern, PhD, Charles G. Cerveny, MS, Leia M. Smith, PhD, Albina Nesterova, MS, Kristine A. Gordon, BS, Iqbal S. Grewal, PhD, Alan F. Wahl, PhD

Blood (2005) 106 (11): 1476.

https://doi.org/10.1182/blood.V106.11.1476.1476

Published: 2005

Journal Articles

A Humanized Anti-CD70 Monoclonal Antibody Targets CD70-Expressing Multiple Myeloma.

Julie A. McEarchern, PhD, Charlotte McDonagh, PhD, Allen Ho, BA, Yu-Tzu Tai, PhD, Leigh Francisco, BS, Kerry Klussman, BS, Carol Morris-Tilden, BS, Kristine Gordon, BS, Ezogelin Oflazoglu, PhD, Kim Kissler, Nikhil Munshi, MD, Kenneth C. Anderson, MD, Steven P. Treon, MD, PhD, Paul Carter, PhD, Alan F. Wahl, PhD, Iqbal S. Grewal, PhD, Che-Leung Law, PhD

Blood (2005) 106 (11): 1591.

https://doi.org/10.1182/blood.V106.11.1591.1591

Published: 2005

NARROW

SGN-CD33A: a novel CD33-targeting antibody–drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML

SGN-CD33A: A Novel CD33-Directed Antibody-Drug Conjugate, Utilizing Pyrrolobenzodiazepine Dimers, Demonstrates Preclinical Antitumor Activity Against Multi-Drug Resistant Human AML

Preclinical and Clinical Binding Properties, Internalization Kinetics, and Clinicopathological Activity of Brentuximab Vedotin (SGN-35): A Novel Antibody Drug Conjugate for Anaplastic Large Cell Lymphoma and Classical Hodgkin Lymphoma

CD27-CD70 interactions in the pathogenesis of Waldenström macroglobulinemia

Preclinical Analysis of the Combined Activity of SGN-40, Anti-CD40 Monoclonal Antibody, with Rituximab in Non-Hodgkin Lymphoma.

SGN-33, Lintuzumab, Demonstrates Anti-Leukemic Activity in Preclinical Models of AML.

SGN-33 Modulates Cytokine and Chemokine Production by Activated Monocytes and Macrophages.

Targeted Depletion and Inhibition of Activated T Lymphocytes with SGN-70, a Humanized Antibody Specific for the Activation Antigen CD70.

Preclinical In Vitro and In Vivo Evidence Support a Therapeutic Role for the CD70 Directed Monoclonal Antibody (SGN-70) in Waldenström’s Macroglobulinemia (WM).

SGN-70, a Humanized Anti-CD70 Antibody, Targets CD70-Expressing Hematologic Tumors.

Engineered anti-CD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities

The Humanized Anti-CD40 Monoclonal Antibody SGN-40 Targets Hodgkin’s Disease Cells through Multiple Mechanisms.

A Humanized Anti-CD70 Monoclonal Antibody Targets CD70-Expressing Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only